Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.91 USD
+0.03 (3.41%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.89 -0.02 (-2.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LCTX 0.91 +0.03(3.41%)
Will LCTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LCTX
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
Other News for LCTX
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance?, at the 59th Annual Inner Ear Biology Workshop
Buy Rating Affirmed for Lineage Cell Therapeutics Amid Strategic Partnerships and Pipeline Progress
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Lineage Cell Therapeutics: A Buy Rating Amidst Financial Stability and Promising Clinical Progress
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript